Mobilization of Allogeneic Peripheral Blood Progenitor Cells

Law, Ping; Lane, Thomas A.

doi:10.1007/978-1-4615-0919-6_3

Cited by 8 publications

(5 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, under conditions of biological stress including systemic infection or following myeloablation prior to marrow transplantation, G-CSF levels may reach as high as 2000 pg/ml [11]. Recombinant G-CSF is now routinely used in the clinical setting to increase circulating white blood cell counts following chemotherapy, or to induce mobilization of blood precursors prior to collecting bone marrow in cases of autologous or donor matched marrow transplantation [12,13].…”

Section: Granulocyte Colony-stimulating Factor (G-csf)mentioning

confidence: 99%

Therapeutic pathways of adult stem cell repair

Ting

Mays

Frey

et al. 2008

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Section: Granulocyte Colony-stimulating Factor (G-csf)mentioning

confidence: 99%

Therapeutic pathways of adult stem cell repair

Ting

Mays

Frey

et al. 2008

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…Recombinant G-CSF is also a common treatment after hematologic disease, or chemotherapy, when white blood cell counts tend to be dangerously low and there is a risk of infection (18). G-CSF is also widely used to induce mobilization of blood precursors in different clinical settings such as chemotherapy-induced myelosuppression and peripheral blood stem cell recollection for autologous and allogeneic bone marrow transplantation (19). In addition, it has been reported that G-CSF in combination with stem cell factors (SCF) improves ventricular remodeling after myocardial infarction (MI) through myocyte regeneration by way of transdifferentiation of BMSCs (20).…”

Section: Recent Studies About Stem-cell Based Therapiesmentioning

confidence: 99%

Homing genes, cell therapy and stroke

et al. 2006

View full text Add to dashboard Cite

Stem cell therapies, such as bone marrow transplantation, are a promising strategy for the treatment of stroke. Bone marrow-derived stem cells (BMSCs) including both hematopoietic and mesenchymal stem cells (HSCs and MSCs) can exhibit tremendous cellular differentiation in numerous organs. BMSCs may also promote structural and functional repair in several organs such as the heart, liver, brain, and skeletal muscle via stem cell plasticity. Interestingly, ischemia is known to induce mobilization of BMSCs in both animal models and humans. The tissue injury is "sensed" by the stem cells and they migrate to the site of damage and undergo differentiation. The plasticity, differentiation, and migratory functions of BMSCs in a given tissue are dependent on the specific signals present in the local micro-environment of the damaged tissue. Therefore, the ischemic micro-environment has critical patho-biological functions that are essential for the seeding, expansion, survival, renewal, growth and differentiation of BMSCs in damaged brain remodeling. Recent studies have identified the specific molecular signals, such as SDF-1/CXCR4, required for the interaction of BMSCs and damaged host tissues. Understanding the exact molecular basis of stem cell plasticity in relation to local ischemic signals could offer new insights to permit better management of stroke and other ischemic disorders. The aim of this review is to summarize recent studies into how BMSCs reach, recognize, and function in cerebral ischemic tissues, with particular regard to phenotypical reprogramming of stem cells, or "stem cell plasticity".

show abstract

“…Healthy donors received random filgrastim (Group I, n. 55) or lenograstim (Group II, n. 46) as mobilizing agent according with the different schedules reported by the literature [21][22][23][24][25][26]. The groups were well balanced for age, body-weight and sex (Table I).…”

Section: Pbpc Mobilizationmentioning

confidence: 99%

“…A dose-response relationship of G-CSF and progenitor cell mobilization has been shown by several investigators [21][22][23][24][25][26]. High doses of G-CSF are generally well tolerated, but may be accompanied by intense muscleskeletal pain [27].…”

Section: Introductionmentioning

confidence: 99%

Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim

et al. 2005

View full text Add to dashboard Cite

Mobilization of CD34+ into peripheral blood is attained by either glycosylated (lenograstim) or non-glycosylated recombinant G-CSF (filgrastim). 101 donors, 57 males, median age 42 years (range 16-63) entered this retrospective study. Group I (55 cases) received filgrastim and group II lenograstim subcutaneously for 5-6 days. The peak number of CD34+ cells/microl blood observed on day 4 and 5 was not significantly different in the two groups. No differences were shown in terms of both circulating CFU-GM at the time of harvesting and CD34+ target of collection. The most frequent side effects were bone pain (18.2% grade I; 36.4% grade II, 7.3% grade III), headache (18.2%), nausea (9.1%), fever (5.5%) and a mild splenomegaly (> 2 cm) (5.5%) in filgrastim group, and bone pain (37.0% grade I, 26.1% grade II, 2.2% grade III), headache (17.4%), nausea (15.2%), fever (4.4%) and a mild splenomegaly (4.3%) in lenograstim group, respectively. CD34+ collection was associated with thrombocytopenia, which was not significantly different between the two groups. No donor in either group developed long-term adverse effects. We conclude that both G-CSFs are comparable in terms of CD34+ cell collection, safety and tolerability.

show abstract

Mobilization of Allogeneic Peripheral Blood Progenitor Cells

Cited by 8 publications

References 96 publications

Therapeutic pathways of adult stem cell repair

Therapeutic pathways of adult stem cell repair

Homing genes, cell therapy and stroke

Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim

Contact Info

Product

Resources

About